Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-B7-H3 antibody-drug conjugate BAT8009

An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) linked to the camptothecin analog exatecan, with potential antineoplastic activity. Upon administration of anti-B7-H3 ADC BAT8009, the anti-B7-H3 antibody moiety targets and binds to B7-H3-expressing tumor cells. Upon binding, internalization and linker cleavage, exatecan is released. Exatecan inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-B7-H3 ADC BAT8009
anti-B7-H3/exatecan ADC BAT8009
anti-B7-H3/exatecan antibody-drug conjugate BAT8009
Code name:BAT 8009
BAT-8009
BAT8009
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search